EichorEICHOR
Study identifier: NCT07319091 Synced from ClinicalTrials.gov · August 04, 2026
● Recruiting

Cystinosis and Mitochondrial Metabolism

Condition: Cystinosis · Native Kidney  ·  Sponsor: Hospices Civils de Lyon

PhaseNA
Planned participants25
Who can joinAll sexes, 2 Years to no upper limit
Healthy volunteersNo

About this study

Cystinosis is a monogenic autosomal recessive lysosomal storage disease with complete penetrance, caused by a biallelic mutation in the CTNS gene (17p13.2) encoding cystinosin, a ubiquitous membrane protein whose role is to clear cystine into the cytosol. Its dysfunction in patients with cystinosis leads to systemic accumulation of cystine, an oxidised dimer of cysteines linked by a disulphide bridge, in the lysosomal space, and irreversible cellular dysfunction. Renal damage is at the forefront, with Fanconi syndrome (proximal tubulopathy) and chronic renal failure developing early in childhood/adolescence. There are also multi-systemic disorders, notably endocrine and ophthalmological. Cysteamine is an amino thiol which reduces the level of intra-lysosomal cystine by breaking the disulphide strands of cystine, giving two cysteines which complex with cysteamine to leave the lysosome. Since the late 1980s, there has been an immediate-release form of the drug, which has considerably improved overall patient survival despite having a major impact on quality of life. This improvement in survival has also led to the emergence of later complications that were not previously observed. This musculoskeletal complication (described in an international consensus in 2019), known as 'CMBD' for Cystinosis Metabolic Bone Disease, may be explained at least in part by an intrinsic defect in the osteoblast and osteoclast that contribute to the human bone phenotype. This intrinsic bone defect …

This description comes directly from the study's public registry record.

Talk to the study team

Justine BACCHETTA, MD  ·  4 27 85 61 30  ·  justine.bacchetta@chu-lyon.fr

Chloé GROSYEUX, MD  ·  chloe.grosyeux@gmail.com

Always discuss trial participation with your own doctor first.

Locations (9)

Service de néphrologie pédiatrique, Hôpital Femme Mère Enfant, Hospices Civils de LyonBron, FranceRecruiting
Service de Néphrologie pédiatrique, Hôpital Jeanne de FlandreLille, FranceRecruiting
Service de néphrologie et exploration fonctionnelle rénale, Hôpital Edouard Herriot, Hospices Civils de LyonLyon, FranceRecruiting
Service de Néphrologie pédiatrique, Hôpital de la TimoneMarseille, FranceRecruiting
Service de Néphologie et endocrinologie pédiatrique, Hôpital Arnaud de VilleneuveMontpellier, FranceRecruiting
Service de Néphrologie pédiatrique, Hôpital Necker-Enfants MaladesParis, FranceRecruiting
Service de Néphrologie-transplantation rénale adultes, Hôpital Necker-Enfants MaladesParis, FranceRecruiting
Service de Néphrologie pédiatrique, Hôpital Robert DebréParis, FranceRecruiting
Service de Néphrologie-Dialyse-Transplantation pédiatrique, Hôpital d'enfants BraboisVandœuvre-lès-Nancy, FranceRecruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →